Pearl River Capital, LLC Allogene Therapeutics, Inc. Transaction History

Pearl River Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $154,614 - $214,684	-4,775 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$18.39 - $54.04 $87,812 - $258,041	4,775 New	4,775 $204,000
Q3 2019 Nov 08, 2019	SELL	$26.11 - $32.99 $19,530 - $24,676	-748 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$25.56 - $31.09 $14,262 - $17,348	558 Added 293.68%	748 $20,000
Q1 2019 May 02, 2019	BUY	$24.82 - $32.54 $4,715 - $6,182	190 New	190 $6,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $233M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.